NY-MORGAN-STANLEY
6.9.2022 17:42:37 CEST | Business Wire | Press release
Morgan Stanley today announced the eighth cohort of the Multicultural Innovation Lab. The in-house accelerator program for technology and technology-enabled startups in the post-seed to Series A funding round stage targets companies with multicultural or women founders, co-founders, CTOs or other C-suite members who are developing innovative solutions across sectors. Now in its sixth year and with 69 total participating companies to date, the program is expanding globally for the first time, with participating companies in both the US and in Europe, the Middle East and Africa (EMEA).
From September 2022 to February 2023, the founders—the majority of whom are women and ethnically diverse—and their companies will participate in a customized accelerator program designed to enhance their growth and development. Chosen from over 2,500 applications, these leaders will benefit from the close support of Morgan Stanley’s global ecosystem of internal and external partners, which will provide a variety of mentorship opportunities and business-growth resources. Through MCIL, Morgan Stanley also makes investments in these early-stage, high-growth startups.
“We are particularly excited to welcome our first global cohort, representing multicultural and women-led innovation in business around the world,” said Selma Bueno, Managing Director and Head of the Multicultural Client Strategy Group. “This new stage in MCIL’s development represents our continued efforts to create a more equitable investment landscape for women- and diverse-led startups and ensure that more overlooked entrepreneurs—and their communities—have the opportunity to succeed.”
The companies that have been selected for the Fall 2022 cohort include the following:
- Advocat is a legal software platform developed to streamline the process of creating and operationalizing legal documents.
- AMAKA Studio is a digital media platform connecting a global community of women sharing Pan-African stories.
- AuditMate is a provider of SaaS-driven vertical transportation maintenance and contract management services. The solution helps property managers with contract analysis, maintenance completion reporting, compliance management and more.
- Gentreo is a software solution helping families and caregivers affordably and easily prepare, plan and protect all they love with next generation estate planning.
- Here Here Market is an online marketplace for food enthusiasts to discover and buy specialty products from ‘chef-prenuers’ and small-batch artisans.
- imagi is an education tech company leveraging proprietary coding education tools to equip girls with essential technology skills and confidence.
- Kami is an AI-powered family support platform providing personalized access to a wide range of wellness consultants, as well as an expertly curated and comprehensive range of guides, articles and tips.
- Perse is a single data technology platform leveraging energy and carbon data from all meters in Britain to report and optimize the energy and carbon footprint for individuals, households and businesses.
- Physician 360 transforms community pharmacies into healthcare clinics by empowering them with access to a virtual care platform.
- Wearisma is a global enterprise SaaS influencer analytics platform helping large-scale companies to optimize marketing spend and to achieve communication objectives.
The Fall cohort will operate in a hybrid environment, using a combination of online video platforms and in-person events to facilitate the curriculum, enhance connectivity and foster community. The program will culminate in the eighth Multicultural Innovation Lab Showcase and Demo Day, when the 10 participating companies will present to potential investors, business partners and customers.
For the last two years, MCIL has been named one of the World’s Best Innovation Labs by Global Finance Magazine. The Lab continues to successfully increase access to capital for diverse entrepreneurs, as evidenced by resulting company acquisitions and additional funding rounds following participation in the program. Some notable examples include:
- Relationship intelligence platform Stimulus raised a $2.5 million seed round to grow partnerships and expand the team with engineering, data science and sales talent.
- Lillii RNB, an AI-powered fraud prevention and investigation SaaS solution for retailers, raised a $3 million seed round from co-leads Serena Ventures and Aperture Venture Capital to capitalize on sales opportunities and grow its partnership network.
- Event management software platform Five to Nine raised a $4.25 million seed round to expand its engineering capability, accelerate product development and grow the team.
About the Multicultural Innovation Lab
The Multicultural Innovation Lab (MCIL) is an intensive five-month in-house accelerator designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MCIL in 2017 in order to address inequities in funding of ethnically diverse- and women-led startups, which our research shows equals over four trillion dollars in unrealized returns.
The team is led by New York-based Selma Bueno, Managing Director and Global Head of the Multicultural Client Strategy Group, and London-based Sanghamitra Karra, Managing Director and EMEA Head of the Multicultural Client Strategy Group. Together, they have over 35 years of investment banking and risk management experience.
Listen to the Access & Opportunity with Carla Harris podcast on your platform of choice to learn about the players driving change among diverse entrepreneurs, the investor community and the world.
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 41 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit https://www.morganstanley.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005822/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom